United Therapeutics Agrees To Buy Miromatrix Medical For $3.25/Share In Cash (An Aggregate Of ~$91M) And An Additional $1.75/Share In Cash Upon The Achievement Of A Clinical Development Milestone
Portfolio Pulse from Benzinga Newsdesk
United Therapeutics has agreed to acquire Miromatrix Medical for $3.25 per share in cash, totaling approximately $91 million. An additional $1.75 per share in cash will be paid upon the achievement of a clinical development milestone.

October 30, 2023 | 10:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Miromatrix Medical is being acquired by United Therapeutics for $3.25 per share in cash, with an additional $1.75 per share upon a clinical development milestone.
The acquisition price of $3.25 per share represents a premium to Miromatrix's current share price. This, along with the additional $1.75 per share upon a clinical development milestone, could positively impact Miromatrix's stock price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100
POSITIVE IMPACT
United Therapeutics is acquiring Miromatrix Medical, which could potentially expand its product portfolio and market reach.
Acquisitions often provide companies with access to new markets, technologies, or products. This acquisition could potentially expand United Therapeutics' product portfolio and market reach, which could positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100